175 related articles for article (PubMed ID: 31165782)
1. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer.
Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer.
Li J; Yao QY; Xue JS; Wang LJ; Yuan Y; Tian XY; Su H; Wang SY; Chen WJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2017 Sep; 38(9):1282-1296. PubMed ID: 28649130
[TBL] [Abstract][Full Text] [Related]
3. Time-dependent pharmacokinetics of dexamethasone and its efficacy in human breast cancer xenograft mice: a semi-mechanism-based pharmacokinetic/pharmacodynamic model.
Li J; Chen R; Yao QY; Liu SJ; Tian XY; Hao CY; Lu W; Zhou TY
Acta Pharmacol Sin; 2018 Mar; 39(3):472-481. PubMed ID: 29119968
[TBL] [Abstract][Full Text] [Related]
4. Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer.
Yuan Y; Zhou X; Ren Y; Zhou S; Wang L; Ji S; Hua M; Li L; Lu W; Zhou T
J Pharm Sci; 2015 Dec; 104(12):4399-4408. PubMed ID: 26344053
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft.
Ma YH; Wang SY; Ren YP; Li J; Guo TJ; Lu W; Zhou TY
Acta Pharmacol Sin; 2019 Feb; 40(2):243-256. PubMed ID: 29773888
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses.
Yao Y; Yao Q; Fu Y; Tian X; An Q; Yang L; Su H; Lu W; Hao C; Zhou T
J Pharm Sci; 2020 Feb; 109(2):1169-1177. PubMed ID: 31655033
[TBL] [Abstract][Full Text] [Related]
7. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice.
Li JY; Ren YP; Yuan Y; Ji SM; Zhou SP; Wang LJ; Mou ZZ; Li L; Lu W; Zhou TY
Acta Pharmacol Sin; 2016 Jul; 37(7):930-40. PubMed ID: 27180983
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden.
Wang S; Zhu X; Han M; Hao F; Lu W; Zhou T
AAPS J; 2020 Feb; 22(2):45. PubMed ID: 32043246
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft.
Hao F; Wang S; Zhu X; Xue J; Li J; Wang L; Li J; Lu W; Zhou T
Pharm Res; 2017 Feb; 34(2):408-418. PubMed ID: 27975187
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Wang H; Li M; Rinehart JJ; Zhang R
Clin Cancer Res; 2004 Mar; 10(5):1633-44. PubMed ID: 15014014
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.
Wang H; Wang Y; Rayburn ER; Hill DL; Rinehart JJ; Zhang R
Int J Oncol; 2007 Apr; 30(4):947-53. PubMed ID: 17332934
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice.
Ji XW; Ji SM; Li RT; Wu KH; Zhu X; Lu W; Zhou TY
Acta Pharmacol Sin; 2016 Jun; 37(6):825-33. PubMed ID: 27133303
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models.
Chen W; Chen R; Li J; Fu Y; Yang L; Su H; Yao Y; Li L; Zhou T; Lu W
J Pharmacol Exp Ther; 2018 Jan; 364(1):13-25. PubMed ID: 29084815
[TBL] [Abstract][Full Text] [Related]
15. Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
Park WS; Park GJ; Han S; Ban S; Park MY; Kim SH; Kim SM; Kim YC; Kim HS; Shin YG; Yim DS
Cancer Chemother Pharmacol; 2017 Aug; 80(2):363-369. PubMed ID: 28660432
[TBL] [Abstract][Full Text] [Related]
16. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
17. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Wang S; Guo P; Wang X; Zhou Q; Gallo JM
Mol Cancer Ther; 2008 Feb; 7(2):407-17. PubMed ID: 18281523
[TBL] [Abstract][Full Text] [Related]
19. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
